Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI- Simcere Pharmaceutical Group, a leading Chinese pharmaceutical and biotech firm, announced March 22 that its biopharmaceutical Endu (recombinant human endostatin injection) for non-small cell lung cancer (NSCLC) has completed Phase IV clinical trials and became the first drug to pass re-registration procedures outlined by China's State FDA

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts